Search results for "Alanine"

showing 10 items of 499 documents

Effect of a dominant-negative form of ADAM10 in a mouse model of Alzheimer's disease.

2009

The alpha-secretase cleaves in the non-amyloidogenic pathway the amyloid-beta protein precursor (AbetaPP) within the region of the amyloid-beta peptides to prevent their formation and aggregation in the brain. Members of the ADAM family (a disintegrin and metalloprotease) are the main candidates for physiologically relevant alpha-secretases. We recently demonstrated that overexpression of ADAM10 in mice transgenic for human AbetaPP (ADAM10 x APP[V717I]) alleviated functional deficits related to Alzheimer's disease. To further demonstrate that this is due to the specific activity of alpha-secretase, we characterized mice overexpressing an inactive form of ADAM10 (ADAM10[E384A]; ADAM10-dn). T…

ADAM10Morris water navigation taskGlutamic AcidStimulationMice TransgenicADAM10 ProteinAmyloid beta-Protein PrecursorMiceIn vivoAlzheimer DiseaseDisintegrinReaction TimeAnimalsHumansIsoleucineProtein precursorMaze LearningSwimmingMetalloproteinaseAlaninebiologyBehavior AnimalChemistryGeneral NeuroscienceAge FactorsMembrane ProteinsValineGeneral MedicineCell biologyMice Inbred C57BLPsychiatry and Mental healthClinical PsychologyADAM ProteinsDisease Models Animalbiology.proteinSpecific activityGeriatrics and GerontologyAmyloid Precursor Protein SecretasesJournal of Alzheimer's disease : JAD
researchProduct

Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease.

2022

Funder: European Commission

ALTtype 2 diabetes mellitusROC receiving operator characteristicaspartate aminotransferaseHSDLDL low-density lipoproteinUHPLC ultrahigh-performance liquid chromatographyROCHCCNon-alcoholic steatohepatitisGCPCANASHGastroenterology2-HB 2-hydroxybutanoic acid; 3-HB 3-hydroxybutanoic acid; ALT alanine aminotransferase; AST aspartate aminotransferase; CE cholesterol ester; Cer ceramide; FFA free fatty acid; FLIP Fatty Liver Inhibition of Progression; Fibrosis; GC gas chromatography; HCC hepatocellular carcinoma; HSD honest significant difference; LC lipid cluster; LDL low-density lipoprotein; LM lipid and metabolite; LMC lipid metabolite and clinical variable; LPC lysophosphatidylcholine; Lipidomics; Mass spectrometry; Metabolomics; NAFL non-alcoholic fatty liver; NAFLD non-alcoholic fatty liver disease; NAS NASH activity score; NASH non-alcoholic steatohepatitis; NIDDK NASH-CRN National Institute of Digestive Diseases and Kidney NASH Clinical Research Network; NRR non-rejection rate; Non-alcoholic steatohepatitis; PC(O) ether PC; PC phosphatidylcholine; PCA principal component analysis; PE phosphatidylethanolamine; QTOFMS quadrupole-time-of-flight mass spectrometry; ROC receiving operator characteristic; SAF steatosis activity and fibrosis; SM sphingomyelin; T2DM type 2 diabetes mellitus; TG triacylglycerol; UHPLC ultrahigh-performance liquid chromatographySAFSAF steatosis activity and fibrosisLM lipid and metabolitehonest significant differenceHSD honest significant differenceTG triacylglycerolnon-rejection ratecholesterol esterPCPEGC gas chromatographyfree fatty acidFLIPNASH non-alcoholic steatohepatitisNIDDK NASH-CRN National Institute of Digestive Diseases and Kidney NASH Clinical Research NetworkBIOMARKERST2DMPE phosphatidylethanolamineLDLlipidNAFLDFFA free fatty acid2-HBMetabolomicsNAFL non-alcoholic fatty liverLMCphosphatidylcholineScience & TechnologySM sphingomyelinGastroenterology & HepatologyMass spectrometryactivitynutritional and metabolic diseasesT2DM type 2 diabetes mellitusACIDSreceiving operator characteristicdigestive system diseasesquadrupole-time-of-flight mass spectrometryLC lipid clusterlow-density lipoproteinNAS2-HB 2-hydroxybutanoic acidNAS NASH activity scoreQTOFMSether PCNRRSCORING SYSTEMprincipal component analysisgas chromatographyLC2-hydroxybutanoic acidPROGRESSIONAST aspartate aminotransferaseLMPC phosphatidylcholinePC(O)MARKERSUHPLCsteatosisTOOLImmunology and AllergyINSULIN-RESISTANCECerSMFatty Liver Inhibition of Progressionhepatocellular carcinoma2-HB 2-hydroxybutanoic acid NIDDK NASH-CRN National Institute of Digestive Diseases and Kidney NASH Clinical Research Network NRR non-rejection rate Non-alcoholic steatohepatitis PC(O) ether PC PC phosphatidylcholine PCA principal component analysis PE phosphatidylethanolamine QTOFMS quadrupole-time-of-flight mass spectrometry ROC receiving operator characteristic SAF steatosis activity and fibrosis SM T2DM type 2 diabetes mellitus TG triacylglycerol UHPLC ultrahigh-performance liquid chromatographyultrahigh-performance liquid chromatographyCELPC3-HBNAFLnon-alcoholic fatty liverTGtriacylglycerolNRR non-rejection rateLife Sciences & BiomedicineNAFLD non-alcoholic fatty liver diseaseFLIP Fatty Liver Inhibition of Progressionalanine aminotransferasemetaboliteCer ceramideCE cholesterol estersphingomyelinlysophosphatidylcholineand fibrosisALT alanine aminotransferaseInternal MedicineceramideNational Institute of Digestive Diseases and Kidney NASH Clinical Research NetworkAST3-HB 3-hydroxybutanoic acidQTOFMS quadrupole-time-of-flight mass spectrometryPCA principal component analysisLPC lysophosphatidylcholineHepatologynon-alcoholic fatty liver diseaseand clinical variablePC(O) ether PC3-hydroxybutanoic acidFibrosisNASH activity scoreNIDDK NASH-CRNlipid clusterlipid and metabolitephosphatidylethanolamineLipidomicsLMC lipid metabolite and clinical variableFFAHCC hepatocellular carcinomaJHEP reports : innovation in hepatology
researchProduct

Giant hepatocellular adenoma as cause of severe abdominal pain: a case report

2007

Abstract The authors describe the case of a large hepatocellular adenoma diagnosed in a 30-year old woman who came to us complaining of acute pain in the upper abdominal quadrants. The patient had been taking an oral contraceptive pill for the last ten years. We present the clinical features, the diagnostic work-up and the treatment prescribed.

Abdominal painPathologyoral contraceptive agent EMTREE medical terms: abdominal painanamnesilcsh:Medicinecomputer assisted tomographyaspartate aminotransferaseSurgical oncologynuclear magnetic resonance imagingMedicine(all)oral contraceptionadultarticleGeneral MedicineAbdominal quadrantsfemalepriority journalhistopathologycontrast enhancementdisease severitymedicine.symptomEMTREE drug terms: alanine aminotransferasemedicine.medical_specialtyOral contraceptive pillcontrast mediummedicinediffusion weighted imagingcase reportfollow uphumanAcute painliver biopsydrug useliver lobectomybusiness.industryGeneral surgeryPublic healthlcsh:RechographyHepatocellular adenomaliver angiographymedicine.diseasetumor bleedinghuman tissueclinical featurenausea and vomitingbusinessaspartate aminotransferase blood levelliver adenomaalanine aminotransferase blood level
researchProduct

Elucidation of the biosynthesis and degradation of allantofuranone by isotopic labelling and fermentation of modified precursors.

2010

Feeding experiments with the ascomycete Allantophomopsis lycopodina indicated that the potent fungistatic allantofuranone is biosynthesized from phenylalanine. Further experiments with synthetic precursors gave evidence that the naturally occurring polyporic acid serves as a key intermediate in the biosynthesis. In addition to the formation of allantofuranone, its abiotic and metabolic degradation were investigated.

Abiotic componentAntifungal AgentsOrganic ChemistryFungiPolyporic acidPhenylalanineBiologyBiochemistryIsotopic labelingchemistry.chemical_compoundBiosynthesischemistryBiochemistry4-ButyrolactoneLabellingIsotope LabelingFermentationMolecular MedicineDegradation (geology)FermentationMolecular BiologyChembiochem : a European journal of chemical biology
researchProduct

Partially competitive inhibition of intestinal baclofen absorption by beta-alanine, a nonessential dietary aminoacid.

1991

In situ intestinal absorption of baclofen in the rat in the presence of beta-alanine has been investigated. Through the perfusion of 0.50 mM baclofen solutions containing variable concentrations of the aminoacid (from 5 to 100 mM), a partially competitive inhibition of baclofen absorption was characterized: absorption rate pseudoconstants of the spasmolytic drug decrease as beta-alanine concentration increases, until a limiting value is obtained (36.8 per cent of that found for baclofen alone). A computer method was developed in order to calculate parameters governing baclofen absorption in the presence of beta-aminoacid, with the following results: Vm = 11.22 mM h-1; Km = 7.42 mM; Ki = 2.4…

Absorption (pharmacology)MaleBaclofenStereochemistryPharmaceutical Sciencebeta-AlanineMichaelis–Menten kineticsIntestinal absorptionchemistry.chemical_compoundNon-competitive inhibitionPharmacokineticsIntestine SmallAnimalsPharmacology (medical)Drug InteractionsPharmacologyChromatographyWaterRats Inbred StrainsGeneral MedicineRatsDietary aminoacidBaclofenchemistryIntestinal Absorptionbeta-AlanineBiopharmaceuticsdrug disposition
researchProduct

Intestinal absorption pathway of gamma-aminobutyric acid in rat small intestine.

1994

Intestinal absorption of gamma-aminobutyric acid (GABA), as a model compound for gamma-aminoacids, has not been extensively studied from the kinetic viewpoint. Since data from our laboratory suggested that some competition arises between intestinal absorption of beta-alanine and GABA and since our intent was to maintain the aqueous stagnant diffusion layer in order to approach absorption tests to in vivo physiological conditions, a rat jejunum in situ study was undertaken in order to gain an insight into the mechanism of GABA absorption. In the present paper, results from assays using isotonic perfusion solutions with starting GABA concentrations ranging from 1 to 50 mM are reported. They s…

Absorption (pharmacology)MalePharmaceutical ScienceMichaelis–Menten kineticsAminobutyric acidIntestinal absorptionDiffusionNon-competitive inhibitionBody WaterIn vivoIntestine SmallmedicineAnimalsPharmacology (medical)Rats WistarChromatography High Pressure Liquidgamma-Aminobutyric AcidPharmacologyAlanineChemistryGeneral MedicineMembrane transportSmall intestineRatsmedicine.anatomical_structureSpectrometry FluorescenceBiochemistryIntestinal AbsorptionBiophysicsBiopharmaceuticsdrug disposition
researchProduct

Evidence of competitive inhibition for the intestinal absorption of baclofen by phenylalanine

1996

Abstract Previous studies showed that the absorption of the antispastic drug baclofen, in the rat middle intestine, is inhibited by β-alanine, γ-aminobutyric acid (GABA) and leucine. It was concluded that baclofen intestinal transport was mediated, at least in part, by the β-, γ- and α-amino acid carriers. We therefore focused our next studies on the analysis of the possible inhibition of drug absorption by an aromatic α-amino acid model compound, phenylalanine. An in situ study in the rat small intestine was undertaken in order to evaluate the effect of phenylalanine on baclofen absorption and to establish the inhibition model. Assays using isotonic perfusion solutions of 0.5 mM baclofen w…

Absorption (pharmacology)medicine.drug_classChemistryPharmaceutical SciencePhenylalanineMuscle relaxantPharmacologyIntestinal absorptionchemistry.chemical_compoundBaclofenNon-competitive inhibitionnervous systemPharmacokineticsmedicineLeucineInternational Journal of Pharmaceutics
researchProduct

New Fluorinated Peptidomimetics through Tandem Aza-Michael Addition to α-Trifluoromethyl Acrylamide Acceptors: Synthesis and Conformational Study in …

2009

A range of partially modified retro (PMR) psi[NHCH(2)] peptide mimetics containing a hydrolytically stable CH(2)CH(CF(3))CO unit have been synthesized. The first kind of peptidomimetics is obtained from the highly efficient aza-Michael addition of different amines to alpha-trifluoromethyl acrylamide acceptors. Subsequent deprotection of the amino group furnishes the key common intermediate for the synthesis of other families of peptidomimetics: dipeptides, tripeptides, peptidomimetics containing a urea moiety, and structures containing two units of alpha-trifluoromethyl-beta(2)-alanine. Finally, a conformational study of several of the newly synthesized peptidomimetics, performed with the a…

AcrylamidesAza CompoundsAlanineMagnetic Resonance SpectroscopyDipeptideTrifluoromethylChemistryTrifluoromethylationStereochemistryFluorine CompoundsOrganic ChemistryMolecular ConformationTripeptideCrystallography X-RayChemical synthesisSolutionschemistry.chemical_compoundCascade reactionpeptidomimeticsMichael reactionMoietyPeptidesThe Journal of Organic Chemistry
researchProduct

Antibodies to hepatitis B core antigen in blood donors screened for alanine aminotransferase level and hepatitis non-A, non-B in recipients.

1988

Four-hundred and seventeen patients undergoing open-heart surgery were followed for more than 9 months after transfusion. All 2270 blood units transfused had alanine aminotransferase levels less than or equal to 30 U/l. Blood units positive for antibodies to hepatitis B core antigen (anti-HBc) were more frequently associated with recipient hepatitis non-A, non-B (HNANB) (13.7%) than anti-HBc-negative units (4.2%) (p less than 0.001). The frequency of HNANB among recipients of at least 1 anti-HBc-positive blood unit (8/79, 10.1%) was fivefold greater than among recipients of exclusively anti-HBc-negative blood units (7/338, 2.1%) (p less than 0.01). In this study the exclusion of donors posi…

AdultAdolescentHepatitis Viral HumanImmunologyBlood DonorsAntigenImmunology and AllergyMedicineHumansAlanine aminotransferaseHepatitis B AntibodiesAgedHepatitisbiologybusiness.industryIncidence (epidemiology)virus diseasesTransfusion ReactionAlanine TransaminaseHematologyMiddle Agedmedicine.diseaseHepatitis B Core AntigensHepatitis Cdigestive system diseasesImmunologybiology.proteinBlood unitsAntibodybusinessDonor screeningHepatitis b coreTransfusion
researchProduct

PET Studies of Net Blood—Brain Clearance of FDOPA to Human Brain: Age-Dependent Decline of [18F]Fluorodopamine Storage Capacity

2005

Conventional methods for the graphical analysis of 6-[18F]fluorodopa (FDOPA)/positron emission tomography (PET) recordings ( Kappin) may be prone to negative bias because of oversubtraction of the precursor pool in the region of interest, and because of diffusion of decarboxylated FDOPA metabolites from the brain. These effects may reduce the sensitivity of FDOPA/PET for the detection of age-related changes in dopamine innervations. To test for these biasing effects, we have used a constrained compartmental analysis to calculate the brain concentrations of the plasma metabolite 3- O-methyl-FDOPA (OMFD) during 120 mins of FDOPA circulation in healthy young, healthy elderly, and Parkinson's …

AdultAgingFluorine Radioisotopesmedicine.medical_specialtyMetaboliteDiffusionCentral nervous system diseasechemistry.chemical_compoundDopamineInternal medicinemedicineHumans18F-fluorodopamineFluorodopamedicine.diagnostic_testbusiness.industryPutamenBrainHuman brainMiddle Agedmedicine.diseaseDihydroxyphenylalanineEndocrinologymedicine.anatomical_structureNeurologychemistryPositron emission tomographyPositron-Emission TomographyNeurology (clinical)Cardiology and Cardiovascular MedicineNuclear medicinebusinessmedicine.drugJournal of Cerebral Blood Flow & Metabolism
researchProduct